资讯
The race to develop muscle-preserving treatments alongside popular obesity drugs like Eli Lillys (NYSE:LLY) Zepbound and Novo ...
At a time when Novo Nordisk has appeared to be slipping behind rival Eli Lilly and its blockbuster Zepbound (tirzepatide) in ...
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...
The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with the U.S., trailing only China.
Investing.com -- The American College of Cardiology released new recommendations on Friday stating that millions more ...
The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs.
10 小时
Barchart on MSNA $1.3 Billion Reason to Buy Eli Lilly Stock NowEli Lilly (LLY) is a pharmaceutical company that focuses on cardiometabolic health, neuroscience, oncology, and immunology.
Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo ...
GLP-1 drugs such as Wegovy and Zepbound are growing increasingly prominent. But some food ingredients can also cause the body ...
14 小时on MSN
Millions more Americans should be taking weight-loss drugs to prevent heart disease, according to the American College of ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly LLY -1.05% ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果